Evidence map›Paper›PMID 14739927›Full record

ArticleThe EMBO journal2004

Regulation of checkpoint kinases through dynamic interaction with Crb2.

Satoru Mochida, Fumiko Esashi, Nobuki Aono, Katsuyuki Tamai, Matthew J O'Connell, Mitsuhiro Yanagida

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Regulatory motifs in Chk1.Cell cycle (Georgetown, Tex.) · 2013
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. BRCT domains: easy as one, two, three.Cell cycle (Georgetown, Tex.) · 2011
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Satoru MochidaGraduate School of Biostudies, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto, Japan.
Fumiko Esashi
Nobuki Aono
Katsuyuki Tamai
Matthew J O'Connell
Mitsuhiro Yanagida
Kyoto University · JPIcahn School of Medicine at Mount Sinai · USMedical & Biological Laboratories (Japan) · JP

Funding

Chk1 signaling in the G2 DNA damage checkpointR01CA100076 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI O'CONNELL, MATTHEW J · 2003 to 2007
$1.7M
Chk1 signaling in the G2 DNA damage checkpointR56CA100076 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI O'CONNELL, MATTHEW J · 2009 to 2009
$336k
NCI NIH HHS CA100076-01NCI NIH HHS R01 CA100076NCI NIH HHS R56 CA100076Wellcome Trust 101009
6 · The paper itself

Abstract

ATR/Rad3-like kinases promote the DNA damage checkpoint through regulating Chk1 that restrains the activation of cyclin-dependent kinases. In fission yeast, Crb2, a BRCT-domain protein that is similar to vertebrate 53BP1, plays a crucial role in establishing this checkpoint. We report here that Crb2 regulates DNA damage checkpoint through temporal and dynamic interactions with Rad3, Chk1 and replication factor Cut5. The active complex formation between Chk1 and Crb2 is regulated by Rad3 and became maximal during the checkpoint arrest. Chk1 activation seems to need two steps of interaction changes: the loss of Rad3-Chk1 and Rad3-Crb2 interactions, and the association between hyperphosphorylated forms of Chk1 and Crb2. Chk1 is the major checkpoint kinase for the arrest of DNA polymerase mutants. The in vitro assay of Chk1 showed that its activation requires the presence of Crb2 BRCT. Hyperphosphorylation of Crb2 is also dependent on its intact BRCT. Finally, we show direct interaction between Rad3 and Crb2, which is inhibitory to Rad3 activity. Hence, Crb2 is the first to interact with both Rad3 and Chk1 kinases.

Indexed as

DNA DamageCell CycleCell Cycle ProteinsCheckpoint Kinase 1Checkpoint Kinase 2DNA-Directed DNA PolymeraseMacromolecular SubstancesMutationNuclear ProteinsProtein KinasesProtein Structure, TertiarySchizosaccharomycesSchizosaccharomyces pombe ProteinsUltraviolet RaysCell Cycle ProteinsCheckpoint Kinase 1Checkpoint Kinase 2Chk1 protein, S pombeCrb2 protein, S pombeDNA-Directed DNA PolymeraseMacromolecular SubstancesNuclear ProteinsProtein Kinasesrad3 protein, S pombeSchizosaccharomyces pombe Proteins

Identifiers

PMID14739927
PMCPMC1271744
OpenAlexW2008543460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.